{"schema_version":"secwatch.filing_event.v1","accession":"0001425450-24-000077","form_type":"8-K","ticker":"KIDS","cik":"0001425450","company_name":"ORTHOPEDIATRICS CORP","filed_at":"2024-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.019616+00:00","generated_at":"2026-05-31T13:03:12.083927+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"OrthoPediatrics reports record Q2 revenue up 33% to $52.8M; net loss widens to $6.0M","bullets":["Q2 2024 revenue $52.8M (+33% YoY); U.S. +39%, Intl +16%. Trauma & Deformity +37%, Scoliosis +26%.","Net loss $6.0M ($0.26/share) vs $2.9M loss ($0.13) in Q2 2023; Adjusted EBITDA $2.6M vs $2.3M.","Reaffirmed FY2024 revenue guidance $200M-$203M (34-36% growth); EBITDA guidance $8M-$9M.","Announced $100M financing (term loan + convertible notes) from Braidwell LP; expects to close Aug 12, 2024.","Approved $5M stock buyback; cash $30.9M (down from $82.3M Dec 2023) due to $5.5M one-time payments."],"urls":{"canonical":"https://secwatch.observer/filing/0001425450-24-000077","json":"https://secwatch.observer/filing/0001425450-24-000077.json","markdown":"https://secwatch.observer/filing/0001425450-24-000077.md","text":"https://secwatch.observer/filing/0001425450-24-000077.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1425450/000142545024000077/0001425450-24-000077-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1425450/000142545024000077/kids-20240805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T13:03:12.083927+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}